SciELO - Scientific Electronic Library Online

 
vol.34 número4Síndrome de seno cavernosoSíndrome de Wellens, equivalente clínico de estenosis coronaria crítica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Medicina interna de México

versión impresa ISSN 0186-4866

Resumen

ESTRADA-MARTINEZ, Luis Enrique et al. Atypical dose of bevacizumab in a patient with Osler-Weber Rendu syndrome. Med. interna Méx. [online]. 2018, vol.34, n.4, pp.649-657. ISSN 0186-4866.  http://dx.doi.org/10.24245/mim.v34i4.1884.

Osler-Weber-Rendu syndrome is an autosomical dominant condition. Although epistaxis is the most frequent symptom, many other visceral implications have to be considered while the workup takes place. While Anti-VEGF are the cornerstone of the treatment, there is no consensus regarding the specific dose to be administered. We communicate de case of a patient with Osler-Weber-Rendu syndrome attended at our Hospital in which we prescribed an atypical dose of bevacizumab with good outcome.

Palabras llave : Osler-Weber-Rendu Syndrome; Bevacizumab; Telangiectasis; Epistaxis.

        · resumen en Español     · texto en Español     · Español ( pdf )